原发性血小板增多症
生物
造血
干细胞
启动(农业)
突变
癌症研究
发病机制
CXCR4型
髓样
造血干细胞
细胞生物学
祖细胞
遗传学
突变体
免疫学
髓系白血病
干扰素
骨髓增生性疾病
巨核细胞
谱系(遗传)
染色质
细胞生长
细胞周期
基因
细胞分化
作者
Jingyuan Tong,Di Wang,Haoze Song,Ting Sun,Yanhong Zhao,Wenjing Gu,Lexuan Lin,Yitong ZHAO,Yipeng Liang,Xu Jin,Rongfeng Fu,Mankai Ju,Jie Gao,Jinfa Ma,Chengjie Gao,Zhang Anqi,Zhijian Xiao,Erlie Jiang,Renchi Yang,Shihui Ma
标识
DOI:10.1002/advs.202505249
摘要
Abstract Essential thrombocythemia (ET) includes the JAK2 ‐, CALR ‐, and MPL ‐mutated subtypes, and a triple‐negative (TN) ET subtype, which lacks these canonical drivers. How specific driver mutations affect hematopoietic stem cell (HSC) heterogeneity and their relation to ET pathogenesis remain unclear. Here, by using single‐cell RNA sequencing (scRNA‐seq) combined with driver mutation detection across ET patients, it is found that MPL ‐mutated HSCs exhibited aberrant metabolism, CALR ‐mutated HSCs displayed active cell cycling, while JAK2 V617F ‐mutated HSCs demonstrated enhanced megakaryocyte (Mk) priming capacity and interferon (IFN) response. An HSC subset is identified in TN ET that transcriptionally resembled driver‐mutated HSCs, exhibiting enhanced megakaryocytic priming and proliferative activity. Notably, the frequency of a CXCR4 + HSC subset is reduced across the ET spectrum. Loss of CXCR4 + HSCs skewed lineage differentiation of HSCs toward the myeloid lineage, whereas restoring this subset delayed the onset of ET. Altogether, this study reveals both the shared and distinct molecular features of mutant HSCs in ET and provides novel insights into the pathogenesis and potential therapeutic strategies of ET.
科研通智能强力驱动
Strongly Powered by AbleSci AI